Among 167 patients in the study, 93 (56%) were patients with lung cancer, of which 46 and 47 patients were treated with non‐PPAR‐γ activating and PPAR‐γ activating ARBs, respectively. This evidence concerns the gene PPARG and lung carcinoma.